Lexeo Therapeutics, Inc. (LXEO)
Nasdaq: LXEO · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2022
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 30, 2026 | Mar 24, 2025 | Mar 11, 2024 | · |
| Revenue | · | · | · | 654 |
| Research and development | 63,797 | 74,091 | 53,130 | 49,162 |
| General and administrative | 45,460 | 31,675 | 15,383 | 12,001 |
| Total operating expenses | 109,257 | 105,766 | 68,513 | 61,163 |
| Operating income | -109,257 | -105,766 | -68,513 | -60,509 |
| Interest expense | 95 | 137 | 205 | 91 |
| Interest and investment income | 6,130 | 7,556 | 2,867 | 1,325 |
| Other income (expense), net | -18 | -9 | -13 | -2 |
| Total non-operating income (expense) | 9,296 | 7,433 | 2,119 | 1,232 |
| Income before income taxes | -99,670 | -98,436r | -66,394 | -59,277 |
| Income tax expense | 0 | 0 | · | · |
| Net income including non-controlling interests | -99,961 | -98,333 | -66,394 | -59,277 |
| Net income | -99,961 | -98,333 | -66,394 | -59,277 |
| Earnings per share, basic | -1.86 | -3.09 | -12.40 | -36.36 |
| Earnings per share, diluted | -1.86 | -3.09 | -12.40 | -36.36 |
| Weighted average shares, basic | 53,645,323 | 31,787,491 | 5,354,368 | 1,630,348 |
| Weighted average shares, diluted | 53,645,323 | 31,787,491 | 5,354,368 | 1,630,348 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding